Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CIOX

    • Most Recent Events

    • 07 Jun 2022 Results of pooled analysis assessing prognostic and predictive value of primary tumor location by using data from five studies (FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 17 Sep 2020 Results (n=688) of pooled analysis assessing biomarker analysis for AREG- and EREG mRNA expression in the FIRE-1, CIOX (FIRE-2) and FIRE-3, published in the Clinical Cancer Research.
    • 31 May 2020 Results of pooled analysis from FIRE-1, CIOX and FIRE-3 presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top